Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT07499414

The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease.

The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. — Recruiting • Non-phase study • Diabetes / Metabolic…

📅 30 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07499414
Start
2026-04-06
Completion
2027-04-05
ClinicaliQ Trial Snapshot
  • The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. — Recruiting • Non-phase study • Diabetes / Metabolic • NCT07499414.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

In humans and most mammals, bile acids play a role in the metabolism of glucose and the transport and absorption of lipids (such as cholesterol and triglycerides), vitamins, and nutrients by allowing for emulsification (mixing) and absorption of fatty molecules that are consumed. More recently, bile acids have been discovered to influence the composition and quantity of the microorganisms in the gut microbiome. Bile acids also act as signalling molecules (like hormones) in the body, regulating important metabolic pathways and digestion. While the majority of bile acids are recycled back…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse
Diabetes / Metabolic · MHRA · 24 Oct 2024
Healthcare professionals are reminded to inform patients about the common and serious side effects associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This…
View brief →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Podcast
GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
Diabetes / Metabolic · 00:15:32 · 03 Apr 2026
GLP-1 receptor agonists mimic gut-derived GLP-1: they increase glucose-dependent insulin release, suppress glucagon and slow gastric emptying. Semaglutide is a once-weekly GLP-1…
Listen →
Guideline
2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease
Diabetes / Metabolic · 30 Mar 2026
This EASD guideline addresses 2022 EASD/ESC Guidelines on Diabetes and Cardiovascular Disease in Diabetes / Metabolic. Use it to review current recommendation…
View guideline →
Guideline
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Diabetes / Metabolic · 27 Mar 2026
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m²…
View guideline →
Clinical Brief
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error
Diabetes / Metabolic · MHRA · 17 Dec 2025
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of med...
View brief →